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Mycobacterium tuberculosis, an etiological agent of pulmo-
nary tuberculosis, causes significant morbidity and mortality
worldwide. Pathogenic mycobacteria survive in the host by sub-
verting host innate immunity. Dendritic cells (DCs) are profes-
sional antigen-presenting cells that are vital for eliciting
immune responses to infectious agents, including pathogenic
mycobacteria. DCs orchestrate distinct Th responses based on
the signals they receive. In this perspective, deciphering the
interactions of the proline-glutamic acid/proline-proline-glu-
tamic acid (PE/PPE) family of proteins of M. tuberculosis with
DCs assumes significant pathophysiological attributes. In this
study, we demonstrate that Rv1917c (PPE34), a representative
member of the proline-proline-glutamic-major polymorphic
tandem repeat family, interacts with TLR2 and triggers func-
tionalmaturationof humanDCs. Signalingperturbations impli-
cated a critical role for integrated cross-talk among PI3K-
MAPK and NF-B signaling cascades in Rv1917c-induced
maturation of DCs. However, this maturation of DCs was asso-
ciated with a secretion of high amounts of anti-inflammatory
cytokine IL-10, whereas Th1-polarizing cytokine IL-12 was not
induced. Consistent with these results, Rv1917c-matured DCs
favored secretion of IL-4, IL-5, and IL-10 fromCD4T cells and
contributed to Th2-skewed cytokine balance ex vivo in healthy
individuals and in patients with pulmonary tuberculosis. Inter-
estingly, the Rv1917c-skewed Th2 immune response involved
induced expression of cyclooxygenase-2 (COX-2) inDCs. Taken
together, these results indicate that Rv1917c facilitates a shift in
the ensuing immunity toward the Th2 phenotype and could aid
in immune evasion by mycobacteria.
Tuberculosis is a chronic infectious disease and a leading
cause of death worldwide (1). A significant increase in myco-
bacterial infections with multidrug-resistant and extensively
drug-resistant strains, variable vaccine efficacy of Mycobacte-
rium bovis bacillus Calmette-Gue´rin, and emergence of tuber-
culosis infection in HIV-infected subjects have emphasized the
need of deciphering pathogenesis of tuberculosis as well as to
identify novel therapeutic targets to combat the disease (2, 3).
Therefore, the functional characterization of mycobacterial
antigens that are potent modulators of host immune responses
to pathogens assumes critical importance. Protective immunity
against intracellular pathogens such asM. tuberculosis depends
principally on cell-mediated immunity executed by efficient
anti-infectious functions of type 1 T helper (Th1) subset of
CD4 T cells (4–6). The polarization of Th1 responses is
orchestrated by IL-12 secreted by antigen-presenting cells
(APCs)7 such as dendritic cells (DCs). A hallmark of Th1-type
CD4 T cells is the production of IFN- that activates a pleth-
ora of innate cell-mediated immunity, including activation of
NK cells, effector functions of cytotoxic T cells, and microbici-
dal properties of macrophages. In contrast, Th2 cells that
secrete IL-4, IL-5, IL-9, and IL-13 are critical for antibody class
switching in B cells as well for inducing a humoral response
(7–10). Th2-driven immunity is significantly efficient in the
eradication of extracellular pathogens butmarkedly deficient in
clearing intracellular infections, including pathogenic myco-
bacteria. Importantly, IL-10 secreted by innate cells such as
DCs and macrophages promotes induction of Th2 responses
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(11, 12). A large body of evidence suggests thatM. tuberculosis
induces the secretion of IL-10 that ultimately suppresses the
secretion of IL-12 and IFN- from APCs and T cells, respec-
tively, culminating in a skewed Th1/Th2 balance toward
unprotective Th2 responses. This eventually leads to inhibition
of the immunoprotective responses of the host with a concom-
itant increase in the vulnerability to chronic mycobacterial
infections (8, 13–15).
Primary polarization of Th cells occurs during their priming
in the secondary lymphoid tissues such as lymph nodes and
spleen. DCs have the unique ability to capture mycobacterial
antigens at the site of infection, mainly alveolar spaces in the
lungs, and tomigrate to lymph nodes where they prime naive T
cells (16, 17). In this complex process, immatureDCs present in
lungs and other tissues are required to undergomaturation and
activation. During this maturation process, DCs lose their
phagocytic capacity and mature into a proficient APCs exhib-
iting higher surface expression of the antigen-presenting mol-
ecules MHC class I and II and costimulatory molecules such as
CD40, CD80, andCD86 and secretion of a large range of immu-
nomodulatory cytokines, all of which determine the type and
strength of Th responses (18, 19).
Sequencing ofM. tuberculosis genome identified PE and PPE
gene clusters, exemplified by the presence of conserved Pro-
Glu (PE) or Pro-Pro-Glu (PPE), near the N terminus of their
gene products (20). The 69 members of the PPE family are fur-
ther subdivided into different subgroups on the basis of differ-
ences in their C-terminalmotif. There are four PPE subfamilies,
one of which, characterized by themotif Gly-Xaa-Xaa-Ser-Val-
Pro-Xaa-Xaa-Trp, constitutes the “PPE-SVP” subfamily, and
the second group is “PPE-PPW,”which includes the highly con-
served Gly-Phe-Xaa-Gly-Thr and Pro-Xaa-Xaa-Pro-Xaa-Xaa-
Trp sequencemotifs at theC terminus. Themajor polymorphic
tandem repeat PPE subfamily contains multiple C-terminal
repeats of the motif Asn-Xaa-Gly-Xaa-Gly-Asn-Xaa-Gly,
whereas the last PPE subfamily consists of proteins with a low
percentage of homology at theC terminus (21, 22). The unique-
ness of the PPE genes is further illustrated by the fact that these
genes are restricted to mycobacteria (20, 23). Many PPE pro-
teins are also known to induce strongT andB cell responses and
to associatewith the cell wall. Following surface exposure, these
PPE proteins could act as agonists to various surface receptors
of APCs resulting in modulation of the host immune responses
(24–28). In this regard, information related to the effects of PPE
antigens on the maturation and functions of human DCs and
the underlying signaling events remains scanty.
In this investigation, we demonstrate that cell wall-asso-
ciated/secretory Rv1917c (PPE34) antigen acts as a TLR2 ago-
nist and induces functional maturation of human DCs.
Rv1917c-matured DCs preferentially secreted IL-10 and trig-
gered IL-4, IL-5, and IL-10 production from CD4 T cells thus
polarizing Th2 responses in vitro. Importantly, skewed Th2 phe-
notype by Rv1917c could also be observed in T cells derived from
tuberculosis patients. Interestingly, Rv1917c-skewed Th2 im-
mune response involved induced expression of cyclooxygenase-2
inDCs.We further demonstrate the signaling integration of PI3K,
MAPK, and NF-B pathways during Rv1917c-triggered matura-
tion ofDCs. These results conjecture that polarization of crucial T
cell responses in favor of Th2 immunity by Rv1917c could aid in
immune evasion bymycobacteria in humans.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents—Recombinant human IL-4, GM-
CSF, and IFN- were purchased from ImmunoTools
(Friesoythe, Germany). Fluorescein isothiocyanate (FITC)-
conjugated monoclonal antibodies (mAbs) to HLA-DR, CD80,
and CD1a and phycoerythrin-conjugated mAbs to CD86 and
CD83 were from BD Biosciences, and phycoerythrin-conju-
gated mAb to CD40 was from BD Biosciences. Anti-Thr-202/
Tyr-204 phospho-ERK1/2, anti-ERK1/2, anti-Thr-180/Tyr-
182 phospho-p38 MAPK, p38 MAPK, anti-NF-B p65
antibodies were purchased from Cell Signaling Technology.
Anti-Ser-473 phospho-Akt antibody was from eBiosciences.
Anti--actin, anti-COX-2, and anti-PGE2 antibodies were
obtained from Sigma. Anti-TLR1, anti-TLR2, anti-TLR4, and
anti-TLR6 were procured from Imgenex. Cell wall, cytosol, cell
membrane, and culture filtrate protein fractions of virulentM.
tuberculosis were obtained from the tuberculosis research
materials and vaccine testing contract at Colorado State
University.
Expression and Purification of SH3-interacting Domain of
Rv1917c—TheSH3-interacting domain of Rv1917c expands from
amino acid 511 to 700 of wild-type protein. In this context, we
cloned the SH3-interacting domain (190 amino acids, 25 kDa) as
well as a larger fragment from amino acids 348 to 824 (476 amino
acids, 55 kDa) encompassing the SH3-interacting domain of
Rv1917cbyPCRamplification fromgenomicDNAusingdomain-
specific primers as follows: 5-CGCGGATCCCCCGCGTCTCC-
GCTTGCGATCGGCTT-3 (forward) and 5-GCTCTAGAG-
GTGCCCGCGATTTCGATCGGGATGT-3 (reverse) for
SH3-interacting domain and 5-GGAATTCCATATGAACAC-
GGGCAGCTTCAATCTA-3 (forward) and 5-CGGGATCCG-
TTGTAGTCGCCGAGGTTTG-3 (reverse) for larger fragment
encompassing the SH3-interacting domain.
The amplified PCR products were ligated into the pJET vec-
tor (Fermentas), and the recombinant clones carrying the
appropriate gene insert were confirmed by DNA sequencing.
The gene insert was subcloned into pET series vectors for pro-
tein expression and purification.Escherichia coliBL21 cells car-
rying recombinant plasmids were induced with isopropyl -D-
thiogalactopyranoside, and His-tagged recombinant proteins
were purified with Ni-nitrilotriacetic acid (Ni-NTA) columns
(Bio-Rad).
Generation of Polyclonal Antibodies to Rv1917c—The poly-
clonal antibodies against Rv1917c were generated in rabbits by
subcutaneous injection of 1 mg of purified SH3-interacting
domain of Rv1917c emulsified with an equal volume of
Freund’s adjuvant (Sigma). The experiments were approved by
the Institutional Ethics Committee for Animal Experimenta-
tion and Institutional Biosafety Committee, Indian Institute of
Science, Bangalore. The first immunization was carried out
with Freund’s complete adjuvant followed by two booster
immunizations with Freund’s incomplete adjuvant at 21-day
intervals. The antibody titers in the serum were determined by
ELISA 2 weeks post final immunization.
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Generation and Culture of Human Dendritic Cells—PBMCs
were isolated from buffy coats of healthy donors purchased
from Hoˆpital Hoˆtel Dieu, Etablissement Franc¸ais du Sang,
Paris, France, upon ethical approval for the use of such materi-
als. Monocytes were positively isolated from PBMCs using
CD14 magnetic beads (Miltenyi Biotec, France). The purity of
themonocytes was98%. Immature DCs were generated from
monocytes by culturing them for 7 days in RPMI 1640medium
containing 10% FCS, 50 units/ml penicillin, 50 g/ml strepto-
mycin, IL-4 (500 IU/106 cells), andGM-CSF (1000 IU/106 cells).
Immature 7-day-old DCs (0.5  106/ml) were cultured with
cytokines alone or cytokines and Rv1917c for 48 h.
Tuberculosis Patients and Healthy Subjects—The study pop-
ulation included tuberculosis bacilli-infected patients (n 11)
or healthy controls (n 4) reporting to theNational Institute of
Mental Health and Neurosciences, Bangalore, India. Active
tuberculosis disease in patients was confirmed by the presence
of acid-fast bacilli in sputum smear examinations and growth of
bacilli in BACTEC cultures as well as by radiological abnormal-
ities in chest x-ray. The healthy subjectswere negative for active
tuberculosis disease. The samples from HIV-positive subjects
were excluded from the study. The study subjects had given
written consent, and the study was approved by the institu-
tional bioethics committee.
Analysis of the Expression of Surface Molecules by Flow Cytom-
etry—Cell surface staining was performed with specifically
labeled mAbs, and samples were processed for flow cytometry
(LSR II, BD Biosciences). For each sample, 5000 events were
recorded. Data were analyzed using BD FACS DIVA software
(BD Biosciences).
Mixed Lymphocyte Reaction—Responder CD4 T cells used
in allogeneicMLRwere isolated fromPBMCs of healthy donors
using CD4magnetic beads (Miltenyi Biotec). DCs were treated
with Rv1917c for 48 h followed by extensive washing and were
co-cultured with 1 105 responder allogeneic CD4 T cells at
DC:T cell ratios of 1:10, 1:20, 1:40, and 1:80. On day 4 of co-
culture, the cells were pulsed for 16–18 h with 0.5 Ci of
[3H]thymidine. Radioactive incorporation was measured by
standard liquid scintillation counting. The proliferation of cells
was measured as counts/min (mean  S.E. of quadruplicate
values) after subtracting values of responder T cell cultures
alone.
Analysis of Cytokines—Cytokines were quantified in cell-free
culture supernatants using BD CBA human inflammation kit
and human Th1/Th2 kits (BD Biosciences).
Treatment of DCs with Pharmacological Inhibitors of Signal-
ing Pathways—All the pharmacological inhibitors were ob-
tained from Calbiochem, reconstituted in sterile DMSO
(Sigma), and used at the following concentrations: LY294002
(50 M), SB203580 (20 M), U0126 (10 M), Bay 11-7082 (20
M), and L-1-tosylamido-2-phenylethyl chloromethyl ketone
(20 M). DMSO at 0.1% concentration was used as the vehicle
control. In all experiments with inhibitors, a tested concentra-
tion was used after careful titration experiments assessing the
viability of the macrophages using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide assay. In experiments
with inhibitors, the cells were treated with a given inhibitor for
60 min followed by treatment with Rv1917c.
Immunoblotting Analysis—Cells were washed with ice-cold
PBS, scraped off the culture dish, and collected by centrifuga-
tion. Cell pellets were lysed, and cell lysates were RIPA buffer
constituting 50 mM Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.25%
sodium deoxycholate, 150mMNaCl, 1 mM EDTA, 1mM PMSF,
1 g/ml each of aprotinin, leupeptin, pepstatin, 1 mM Na3VO4,
1 mM NaF. Protein concentration in each cell lysate was
determined by Bradford’s method of protein detection. Equal
protein amounts from each cell lysate were subjected to SDS-
PAGE and transferred onto polyvinylidene difluoride mem-
branes (Millipore) by the semidry Western blotting (Bio-Rad)
method. Nonspecific binding was blocked with 5% nonfat dry
milk powder in TBST (20mMTris-HCl (pH 7.4), 137mMNaCl,
and 0.1% Tween 20) for 60min. The blots were incubated over-
night at 4 °C with primary antibodies diluted in TBST with 5%
BSA. After washing with TBST, blots were incubated with anti-
rabbit or anti-mouse IgG secondary antibody conjugated to
HRP (Jackson ImmunoResearch) diluted in TBSTwith 5% BSA
for 2 h. After further washing in TBST, the immunoblots were
developed with the ECL system (PerkinElmer Life Sciences)
following the manufacturer’s instructions.
Nuclear and Cytosolic Subcellular Fractionation—DCs were
cultured in 35-mm dishes and treated as indicated. After treat-
ment, cells were harvested by centrifugation at 13,000 rpm for 5
min, and cell pellets were washed with phosphate-buffered
saline (PBS) and gently resuspended in ice-cold Buffer A (10
mMHEPES (pH 7.9), 10mMKCl, 0.1 mM EDTA, 0.1mM EGTA,
1 mM DTT, and 0.5 mM PMSF). After incubation on ice for 15
min, cell membranes were disrupted with 10% Nonidet P-40,
and the nuclear pellets were recovered by centrifugation
13,000 g for 15 min at 4 °C, and the supernatant was used as
cytosolic extract. Nuclear pellets were lysed with ice-cold
Buffer C (20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1
mM EGTA, 1 mM DTT, and 1 mM PMSF), and nuclear extracts
were collected after centrifugation at 13,000  g for 20 min at
4 °C.
Transient Transfections and Immunofluorescence—For im-
munofluorescence studies, HEK-293 cells or DCs were seeded
in 35-mm dishes on coverslips. HEK-293 cells were transfected
with indicated plasmid construct (Vector or TLR2 cDNA con-
struct) using ESCORT III (Sigma). HEK-293 cells were treated
with 2 g/ml FITC-labeled Rv1917c for 1 h, and DCs were
pretreated with either anti-TLR1, TLR2, TLR4, TLR6 blocking
antibodies, or isotype control antibodies for 1 h followed by
treatment with FITC-labeled Rv1917c. Cells were washed and
fixed with coldmethanol for 15min at room temperature. Cov-
erslips with cells weremounted on a slide with Fluoromount G.
Immunofluorescent images were acquired by confocal micros-
copy (Carl Zeiss, Germany), and the images were analyzed for
the integrated density of the fluorescence and for the area of the
cells using Zeiss LSM image browser software.
Immunoprecipitation Assay—Vector or TLR2 cDNA con-
struct-transfected HEK-293 cells and DCs were washed briefly
with ice-cold PBS, and cell lysates were prepared in 1 RIPA
lysis buffer (50 mM Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.25%
sodium deoxycholate, 150mMNaCl, 1 mM EDTA, 1mM PMSF,
1 g/ml each of aprotinin, leupeptin, pepstatin, 1 mM Na3VO4,
1 mM NaF). The cell lysate was incubated with Rv1917c immo-
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bilized on Ni-NTA beads at 4 °C overnight on a rotor. The
beadswere harvested, washed, and boiled in 5Laemmli buffer
for 5 min. The proteins were separated on 12% SDS-PAGE fol-
lowed by transfer of proteins to polyvinylidene difluoridemem-
branes (Millipore). The membranes were further probed with
anti-TLR1, -TLR2, -TLR4, or -TLR6 antibodies as indicated.
Statistical Analysis—Levels of significance for comparison
between samples were determined by the Student’s t test distri-
bution. The data in the graphs are expressed as themean S.E.
GraphPadPrism3.0 software (GraphPad software)was used for
all statistical analyses.
RESULTS
Rv1917c Induces Maturation of Human Dendritic Cells—
The recent reports suggest that the PPE gene family can serve
an important role in host-pathogen interactions bymodulating
innate immune responses during tuberculosis infection and
hence can regulate the clinical course of tuberculosis (24–28).
Because DCs are professional APCs and are important for elic-
iting both primary and secondary immune responses to patho-
gens, we explored whether Rv1917c, a typical member of PPE
family, can regulate maturation of human DCs. Rv1917c open
reading frame (ORF) encodes for protein with molecular mass
equivalent to 143 kDa. Previous report had demonstrated the
presence of Rv1917c in the cell wall but not in the culture fil-
trate fractions suggesting that Rv1917c could be a strongly
hydrophobic protein and might not exhibit secretory proper-
ties (29). Furthermore, we assessed the localization of Rv1917c
in various cellular fractions of virulent M. tuberculosis, and as
demonstrated in supplemental Fig. S1, Rv1917c could be
detected in the cell wall and cell membrane but not in the
cytosol and culture filtrate fractions. Importantly, assessment
of the purity of cell wall fractions was carried out by probing the
cellular fractions with monoclonal antibodies reactive to cyto-
solic catalase-peroxidase KatG ofM. tuberculosis.Accordingly,
whereas the cytosolic fraction exhibited reactivity to antibodies
against KatG, the cell wall fraction did not demonstrate any
presence of KatG, thereby validating the purity of the cell wall
preparations (data not shown).
In addition, preliminary in silico analysis of Rv1917cwas per-
formed to identify potential domains of importance, and a
search against the domain data base demonstrated the presence
of four eukaryotic SH3-interactingmotifs PXXP in the region of
protein expanding from amino acid 511 to 700. SH3 domains
are 60-residue modules that often occur in signaling and
cytoskeletal proteins and regulate a variety of cell fate decisions
by virtue of their interaction with proline-rich interacting
motifs PXXP in several eukaryotic as well as prokaryotic pro-
teins (30–32). In this context, we cloned and expressed SH3-
interacting domain (190 amino acids, 25 kDa) as well as a larger
fragment encompassing the SH3-interacting domain of
Rv1917c from amino acid 348–824 (476 amino acids, 55 kDa).
Majority of the experiments were performed utilizing purified
SH3-interacting domain, and results were also validated with a
larger fragment of Rv1917c encompassing the SH3-interacting
domain (supplemental Fig. S2).
Immature DCs were cultured with Rv1917c for 48 h, and
expression of various cell surface markers was analyzed by flow
cytometry. A protein concentration of 5 g/ml was utilized in
all these experiments after titration analysis. Rv1917c enhanced
the expression of co-stimulatory molecules CD80, CD86, and
CD40 (Fig. 1, A and B). Furthermore, Rv1917c treatment aug-
mented the expression of DC terminal maturation marker
CD83 (Fig. 1, A and B). A decrease in the expression of DC
differentiation marker CD1a is a well defined marker for DC
maturation (33, 34). When analyzed, Rv1917c decreased CD1a
expression onDCs (Fig. 1B). In addition, expression of the anti-
gen-presenting molecule, HLA-DR, was also enhanced, further
validating DC maturation potential of Rv1917c.
Several lines of evidence indicate that the maturation of DCs
induced by Rv1917c was not due to contaminating endotoxins
or LPS. For all experiments, we used purified Rv1917c protein
preparations that were passed through a polymyxin B-agarose
column. Accordingly, we could not detect endotoxins in pro-
tein preparations as analyzed by the E-Toxate kit (Sigma).
Furthermore, an unrelated His-tagged mycobacterial lipase
protein produced and processed by the same procedure failed
to trigger maturation of DCs (33). Importantly, proteinase K
treatment abrogated the ability of Rv1917c to induce matura-
tion of DCs as analyzed by cell surface expression of CD80,
CD86, CD83, CD40, HLA-DR, and CD1a indicating that the
maturation of DCs was induced by intact Rv1917c protein and
not by contaminating endotoxins (supplemental Fig. S3).
Rv1917c Triggers the Secretion of Immunomodulatory Cyto-
kines by DCs—DCs secrete a wide range of cytokines that reg-
ulate inflammation and adaptive T cell responses. As a “proof of
concept,” we therefore analyzed whether the maturation pro-
cess of DCs induced by Rv1917c is coupledwith the secretion of
immunomodulatory cytokines such as IL-6, IL-8, IL-10, IL-12,
and TNF-. As demonstrated in Fig. 2, A–D, Rv1917c-stimu-
lated DCs secrete high levels of IL-6, IL-8, TNF-, as well as
immunoregulatory, suppressive cytokine IL-10. Interestingly,
Rv1917c failed to trigger secretion of pro-inflammatory and
Th1-promoting cytokine IL-12 (Fig. 2E).
Rv1917c-stimulatedDCs Induce CD4TCell Proliferation in
Vitro—One of the functional attributes of DCs is their signifi-
cant ability to stimulate CD4 T cells at very low stimulator to
responder ratios (18, 19, 35). The priming of T cell responses by
DCs is regulated by several receptor-ligand interactions such as
engagement of the peptide-MHC complex with T cell receptor
of T cells (signal 1) and of co-stimulatory CD80/CD86, CD40,
and adhesion molecules CD54 and CD58 on DCs with CD28,
CD154, CD11a, and CD2, respectively, on T cells (signal 2) (18,
19, 35, 36). To ascertain that Rv1917c antigen-matured DCs
were potent T cell stimulators, allogeneic T cells were co-cul-
tured with them at various DC:T cell ratios, and the extent of T
cell stimulation was assayed by measuring thymidine incorpo-
ration. As demonstrated in Fig. 3A, Rv1917c-stimulated DCs
stimulated CD4T cells at ratios as low as 1:80, thus indicating
that Rv1917c matured DCs were efficient T cell stimulators.
In addition to providing co-stimulatory signaling to CD4 T
cells, activatedDCs secrete awide range of immunomodulatory
cytokines that regulate the polarization of CD4T cells toward
different subtypes such as Th1, Th2, or Th17. Whereas IL-12
signals for differentiation of Th1 cells, IL-4 and IL-10 promote
Th2 differentiation (18, 19, 35). Therefore, in the context of
Rv1917c-drivenMaturation of HumanDCs and Th2 Responses
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tuberculosis, DCs can bias CD4 T cell priming toward a pro-
tective Th1 or immunosuppressive Th2 responses. Consistent
with the pattern of cytokines secreted (Fig. 2E), Rv1917c-ma-
tured DCs promoted an augmented
secretion of IL-4, IL-5, and IL-10 by
CD4 T cells (Fig. 3B). Interest-
ingly, Rv1917c-stimulated T cells
produced negligible levels of IFN-
(Fig. 3B). These results clearly sug-
gest that Rv1917c-matured DCs
induce Th2-biased response as
against the reported Th1 response
induced by diverse mycobacterial
antigens (33, 37).
Rv1917c Skews Th1/Th2 Balance
toward Th2 ex Vivo—Because
Rv1917c-matured DCs have the
potential to shift the balance of
immunity in favor of Th2, we
hypothesized that patients with pul-
monary tuberculosis have a high
frequency of T cells specific to
Rv1917c and these T cells exhibit a
strong Th2-biased phenotype. In
consensus with our hypothesis, Rv1917c elicited robust IL-5
secretion from T cells of patients with pulmonary tuberculosis
compared with healthy individuals (Fig. 3C). Interestingly,
FIGURE 1. Recombinant Rv1917c inducesmaturation of humanDCs. A and B, 7-day-old immature DCs (0.5 106 cells/ml) were cultured with GM-CSF and
IL-4 alone (Control) or GM-CSF, IL-4, and 5 g/ml of Rv1917c for 48 h followed by analysis for the expression of surface markers by flow cytometry. The
percentage of cells expressing the indicatedmarkers is shown in A, andmean fluorescence intensities (MFI) are shown in B. Data are presented asmean S.E.
from five independent donors. *, p 0.05 versus control.
FIGURE 2. Rv1917c triggers secretion of immunoregulatory cytokines fromhumanDCs. A–E,DCs (0.5 106
cells/ml) were culturedwith GM-CSF and IL-4 alone (Control) or GM-CSF, IL-4, and 5g/ml of Rv1917c for 48 h, and
secretion of IL-6 (A), IL-8 (B), TNF- (C), IL-10 (D), and IL-12 (E) in cell-free culture supernatants was analyzed by
cytokinebeadarrayassay.DataarepresentedasmeanS.E. fromsix independentdonors. *,p0.05versuscontrol.
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Rv1917c did not induce secretion of IFN- from T cells of
tuberculosis patients. Furthermore, the median ratio of
Rv1917c-induced IFN-/IL-5 in tuberculosis patients as well as
healthy individuals advocated the Th2 polarizing nature of
Rv1917c (data not shown).
Rv1917c Interacts with TLR2—Pattern recognition receptors
(PRRs), a class of innate immune response-expressed proteins,
have the ability to recognize pathogen-associated molecular
patterns in mycobacteria or cell wall antigens of mycobacteria.
Among other PRRs, Toll-like receptors (TLRs) occupy a central
place in host defense against invading pathogens, including
mycobacteria, by activating intracellular signaling cascades,
activation of innate cells, and secretion of inflammatory cyto-
kines (37–42).
Earlier reports suggest that mycobacteria harbor antigens
with the potential to interact with TLR1, TLR2, TLR4, and
TLR6 that could have differential effects on ensuing host
immune responses (37, 41, 43–49). In view of these observa-
tions, we analyzed the possible interaction of Rv1917c with dif-
ferent TLRs. A series of pulldown assays were performed to
explore possible interaction of Rv1917c to various TLRs, and
results signify that Rv1917c physically interacts with TLR2 (Fig.
4A). To further ascertain the spe-
cific binding of Rv1917c with TLR2,
we blocked TLR1, TLR2, TLR4, and
TLR6 by respective blocking anti-
bodies and then analyzed binding of
FITC-labeled Rv1917c to the cell
surface of DCs. As demonstrated in
Fig. 4B, blockade of TLR2, but not
that of TLR1, TLR4, and TLR6,
abrogated binding of Rv1917c to the
DC surface. For further validation,
HEK-293 cells, a human embryonic
kidney cell line that lacks TLR2,
were transfected with TLR2 expres-
sion construct, and the binding of
Rv1917c to HEK-293 cells was ana-
lyzed. Results presented in Fig. 4C
demonstrate that Rv1917c interacts
preferentially with TLR2-trans-
fected HEK-293 cells in comparison
with vector-transfected cells. Simi-
larly, Rv1917c could pull down
TLR2 from TLR2-transfected HEK-
293 cells thus further confirming
the ligand potential of Rv1917c for
TLR2 (Fig. 4D). These results clearly
ascertain Rv1917c as a specific
TLR2 agonist that could have a
probable role in cell fate decisions.
Integrated Cross-talk of PI3K,
MAPK, and NF-B Signaling Path-
ways during Rv1917c-induced Mat-
uration of Human DCs—Thematu-
ration of DCs often involves diverse
sets of signaling events, and many
species of mycobacteria are known
to trigger the activation of PI3K/Akt and MAPK, including
ERK1/2 and p38 MAPK (33, 50–57). Among the transcription
factors, the active heterodimer p50/p65 forms of nuclear fac-
tor-B (NF-B) has been suggested to play a central role in
immunological processes by inducing expression of a variety of
genes involved in inflammatory responses (50, 51, 54, 57, 58). In
this regard, Rv1917c triggered the activation of Akt as well as
MAPKs, ERK1/2, and p38MAPK (Fig. 5A). Interestingly, phar-
macological inhibition data suggest that Rv1917c-mediated
activation of ERK, but not p38 MAPK, required the involve-
ment of PI3K (Fig. 5B). Accordingly, Rv1917c induced
significant nuclear translocation of NF-B from cytosol within
60min of stimulation (Fig. 5C). The pharmacological inhibition
of PI3K (LY294002), ERK1/2 (U0126), and p38 MAPK
(SB203580) abrogated Rv1917c-articulated nuclear transloca-
tion of NF-B (Fig. 5D). These results clearly suggest a signifi-
cant role of PI3K- and MAPK-dependent NF-B activation
during Rv1917c-induced DC maturation.
Furthermore, U0126 (ERK1/2 inhibitor), SB203580 (p38
MAPK inhibitor), LY294002 (PI3K inhibitor), Bay 11-082 or
L-1-tosylamido-2-phenylethyl chloromethyl ketone (NF-B
inhibitor) abrogated Rv1917c-induced expression of DCmatu-
FIGURE 3. Rv1917c-treated DCs stimulate CD4 T cells to produce Th2 cytokines. A and B, DCs were
cultured with GM-CSF and IL-4 alone (Control) or GM-CSF, IL-4, and 5g/ml of Rv1917c for 48 h. The Rv1917c-
matured DCs were co-cultured with allogeneic CD4 T cells at different DC to T cell ratios. After 4 days of
co-culture, the cells were pulsed overnight with 0.5 Ci of [3H]thymidine to quantify T cell proliferation (A).
Radioactive incorporation was expressed as counts/min (mean  S.E. of quadruplet values). The data are
representative for three independent donors. B, cell-free supernatants from DC:T cell co-cultures were ana-
lyzed for the cytokines IL-4, IL-5, IL-10, and IFN-. C, PBMCs obtained from tuberculosis patients (TB patients)
(n  11) and healthy control subjects (n  4) were cultured with or without 5 g/ml Rv1917c, and cell-free
supernatants collected on day 4 were tested for concentrations of secreted IL-5 and IFN-. Data are repre-
sented as mean S.E. *, p 0.05 versus control; **, p 0.05 versus Rv1917c (Healthy Controls).
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ration markers CD80, CD86, CD40, CD83, and HLA-DR,
whereas rescued Rv1917c triggered decrease in CD1a expres-
sion (Fig. 6A and supplemental Fig. S4). In addition, inhibition
of PI3K, ERK1/2, p38 MAPK, and NF-B abolished Rv1917c-
induced secretion of cytokines IL-6 and IL-10 as well as TNF-
from DCs (Fig. 6B). Altogether, these observations clearly
implicate a role for signaling integration between members of
PI3K, MAPK, and NF-B pathways in Rv1917c-triggered mat-
uration of human DCs.
Critical Role for COX-2 in Rv1917c-triggered Th2 Response—
Increasing evidence supports the multifaceted effect of pros-
tanoids like PGE2 on T cell differentiation. PGE2 has been
shown to decrease IL-12 and increase IL-10 production by DCs
andmacrophages. PGE2modulates a wide range of T cell effec-
tor functions, including promotion of the development of Th2
responses and inhibition of the production of Th1 cytokines
IL-2 and IFN- (45, 56, 59). PGE2 is a biosynthetic product of an
enzymatic reaction catalyzed by cycloxygenase-2 (COX-2).
Thus PGE2 levels in cellular systems are tightly regulated by
COX-2 activity (60, 61). In this context and consistent with the
production of IL-10 by Rv1917c-stimulated DCs and promo-
tion of Th2 responses by Rv1917c-educatedDCs (Fig. 2 and Fig.
3, B and C), Rv1917c augmented expression and secretion of
COX-2 and PGE2, respectively, in human DCs (Fig. 7, A and
B). Furthermore, pharmacological
inhibitor NS-398-mediated inhibi-
tion of COX-2 activity led to a
decrease in Rv1917c-triggered
secretion of immunosuppressive
cytokine IL-10 in human DCs (data
not shown). Interestingly, pretreat-
ment of DCs with NS-398 has
blocked Rv1917c-triggered secre-
tion of Th2 cytokines IL-5 and IL-10
from T cells (Fig. 7C). These obser-
vations thus demonstrate that
induced expression of COX-2/
PGE2 represents a critical factor
in Rv1917c-triggered Th2-biased
immune responses.
DISCUSSION
A protective anti-mycobacterial
immune response includes activa-
tion of Th1 CD4 T cells resulting
in release of microbicidal IFN- (5).
However, patients with active
tuberculosis exhibit biased Th2
immune responses during later
stages of the infection conveying
severity of the disease (62). DCs are
known to prime and modulate T
cell-mediated immunity toward
mycobacterial antigens. Mycobac-
terial infection or its antigens
could interfere in DC maturation
and subsequent effector functions
thus representing a novel immune
evasion mechanism by mycobacteria (63–65). Although
mycobacteria reside within phagolysosomes, diverse cell
wall-associated antigens such as lipoarabinomannan, phos-
phatidylmyoinositol mannosides, PE/PPE antigens actively
traffic out and access both intracellular compartments as
well as extracellular environment (66–69). These findings
strengthen the need to delineate the interaction of these
antigens with human DCs to effectuate deeper insights into
disease pathogenesis as well as to identify and develop cred-
ible vaccine candidates.
Many of the cell wall-associated or secreted antigens of
pathogenic mycobacteria are conjectured to execute subver-
sion of immune responses. For example, ESAT-6 inhibits
effector functions of APCs by modulating TLR2-mediated
signaling leading to inhibition of the activities of NF-B and
interferon regulatory factors (70). In addition, mannose-
capped lipoarabinomannan induces expansion of regulatory
T cells, whereas 10-kDa culture filtrate protein (CFP-10)
down-regulates Th1 responses against mycobacterial anti-
gens by modulating maturation of DCs (64). In this regard,
restriction of the distinctive PE/PPE family of antigens to
mycobacterial species as well as their unique expression pro-
files upon infection suggest their important role in adapta-
tion or persistence of the pathogenic mycobacteria. Further-
FIGURE 4.Rv1917c specifically recognizes TLR2on cell surface.A, cell lysates fromDCswere incubatedwith
Rv1917c immobilized on Ni-NTA beads, and bead-bound proteins were analyzed for TLR1, TLR2, TLR4, and
TLR6 by immunoblotting. B, DCs were pretreated with either blocking antibodies against TLR1, TLR2, TLR4,
TLR6, or isotypic control antibodies followed by incubation with FITC-labeled Rv1917c, and interaction of
Rv1917c with DCs was evaluated by confocal microscopy. C, preferential interaction of FITC-labeled Rv1917c
with TLR2 cDNA-transfected HEK-293 cells. D, cell lysates from HEK-293 cells transfected with either TLR2 or
vector were incubated with Rv1917c immobilized on Ni-NTA beads, and immunoprecipitation of TLR2 was
evaluated. BF, Bright Field. Data are representative of two independent experiments.
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more, multiple PPE antigens such as Rv2430c, Rv2608, and
Rv3347c were found to be recognized by antibodies in the
sera of infected patients suggesting elicitation of strong B
cell responses to these antigens in patients with tuberculosis
(28, 71, 72). Rv1196 was demonstrated to interact with TLR2
on the macrophage cell surface and induce IL-10 secretion
(45). Furthermore, a transposon insertion mutant of
Rv3018c exhibited attenuated growth in macrophages, sug-
gesting a role in survival of the bacterium (73). However,
there is no report deciphering the immunological conse-
quences of interaction of PPE antigens with human DCs.
In this context, we explored the effect of Rv1917c on acti-
vation and maturation of human DCs and its possible out-
come in terms of the clinical course of tuberculosis. Rv1917c,
a representative member of major polymorphic tandem
repeat subfamily of PPE antigens, is surface-exposed, pre-
dicted to contain many putative O-glycosylation sites, and
display high antigenic index (29). Interestingly, Rv1917c has
been demonstrated to exhibit tandem repeat polymorphism
among clinical isolates of M. tuberculosis (29, 74). Further-
more, DNA microarray expression data suggested selective
enhancement in the expression of Rv1917c in M. tuberculo-
sis bacilli during infection of mouse macrophages (75).
Rv1917c exhibited strong humoral reactivity with cerebro-
spinal fluid of tuberculous meningitis patients attributing
association of Rv1917c antigen in pathophysiological condi-
tions of tuberculosis.8 Interest-
ingly, as described previously,
bioinformatics analysis using
Motif Scan revealed the presence
of four SH3-interacting motifs in
Rv1917c expanding from amino
acid 511 to 700. SH3-interactive
domains across many proteins,
including those that function as
critical players in signal transduc-
tion events, often act as rate-limit-
ing factors in effectuating the
overall immune responses. Impor-
tantly, a prominent high incidence
of SH3-interacting motifs in
mycobacterial proteins such as
Rv1917c suggest a possible inter-
action of these proteins with SH3
domain-containing proteins of var-
ious immune cells (31). In addition
to mycobacterial cell wall localiza-
tion, homology domain modeling
ascertained possible cross-talk of
Rv1917c with the molecules of host
signaling pathways. In the perspec-
tive of this study, the presence of
SH3-interacting domain clearly
ascribes an immunomodulatory
role for Rv1917c, a surface-exposed
prototype member of PPE family
proteins of M. tuberculosis. In the
view of these observations, Rv1917c
represents as an ideal PPE antigen prototype to studymycobac-
teria-specific innate immune responses in humans.
In this regard, we explored the implication of the SH3-inter-
acting domain of Rv1917c in modulation of human DC matu-
ration and in turn regulation of host immune responses. Our
observations suggest that SH3-interacting domain of Rv1917c
induces maturation of human DCs as assessed by analysis of
phenotypic markers and cytokine secretion. Interestingly,
although Rv1917c augmented in DCs the secretion of IL-10, it
did not induce IL-12, a Th1-polarizing cytokine. In addition,
Rv1917c-matured DCs were functionally competent as
assessed by proliferation of CD4 T cells. However, quantita-
tive analysis of secreted cytokines revealed the potential of
Rv1917c to skew the immune response in favor of Th2
immunity.
O-Glycosylation usually strongly influences the immune
response; and to rule out the role of O-glycosylation in
Rv1917c-inducedmaturation of humanDCs, the SH3-interact-
ing domain as well as a larger fragment encompassing the SH3-
interacting domain of Rv1917c were expressed and purified
using E. coli BL21 expression system. In addition, although the
NetOGlyc program predicted a number of putativeO-glycosyl-
ation sites, it failed to detect the presence of signal peptide
8 K. N. Balaji, unpublished data.
FIGURE 5. DC maturation triggered by Rv1917c involves PI3K, ERK1/2, and p38 MAPK-dependent acti-
vation of NF-B. A, DCs were treated with Rv1917c for indicated time points, and phosphorylation of ERK1/2
(pERK1/2), p38 MAPK (pp38), and AKT (pAKT) was analyzed by immunoblotting. B, DCs were pretreated with
LY294002 followed by stimulation with Rv1917c for indicated time points, and activation of ERK1/2 and p38
MAPK was analyzed. C, Rv1917c and LPS trigger nuclear translocation of p65 NF-B. D, DCs were pretreated
with ERK1/2 inhibitor (U0126, 10M), p38MAPK inhibitor (SB203580, 20M), and PI3K inhibitor (LY294002, 50
M) followed by treatment with Rv1917c and nuclear translocation of p65 NF-B was analyzed.Med,Medium.
Data are representative of three independent experiments.
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for O-glycosylation in full-length as well as SH3-interacting
domain or a larger fragment encompassing the SH3-inter-
acting domain of Rv1917c. These results are in agreement
with findings of a recent report, wherein staining with the
glycan/protein double labeling kit (Roche Applied Science)
and detection with the concanavalin A lectin failed to dem-
onstrate glycosylation of Rv1917c (29). These results clearly
suggest that Rv1917c might not be O-glycosylated during in
vivo conditions.
Activation of host innate immunity is initiated by evolution-
ally conserved PRRs like TLRs that recognize pathogen-associ-
ated molecular patterns (42). Among TLRs, TLR2 acquires a
unique place in terms of mycobacterial pathogenesis as it
appears to be one of the major PRRs interacting with this orga-
nism (37, 38, 70). Interestingly, TLR2 is known to heterodimer-
ize and activate the immune response in conjunction with
TLR1 or TLR6 orDectin1 (43, 46, 49, 76). However, the original
concept suggesting role for TLR2/TLR1 and TLR2/TLR6 het-
eromers in recognition by various antigens has recently been
confronted by a report suggesting that certain TLR2 agonists
can stimulate cells from TLR1- or TLR6-deficient mice. These
observations suggest the existence of multiple separate recog-
nition pathways, including TLR2/TLR1, TLR2/TLR6, and
TLR2 alone, which could function independent of each other
(77). During infection, the activation of TLR2 in DCs has a
pivotal function in their functional maturation that ulti-
mately controls the strength of innate and acquired immune
responses. Although NF-B activation is a critical factor,
activation of ERK1/2, p38 MAPK, and PI3K pathways
assumes a rate-limiting step in DCmaturation that regulates
the strength of immune response and leads to generation of
pathogen-tailored immune responses (50, 57, 58). Impor-
tantly, recent reports have suggested that activation of dif-
ferential intracellular signaling pathways upon TLR ligation
can lead to alternative T cell-mediated responses. It has been
demonstrated that ERK/p38 MAPK activation ratio controls
the Th1/Th2 switch and a high ERK/p38 MAPK activation
ratio can promote pro-Th2 maturation via increased IL-10
release and diminished IL-12 synthesis (55, 78). In this con-
text, TLR2-specific interaction of Rv1917c as opposed to
TLR1 or TLR6 suggests that Rv1917c could utilize the TLR2
alone cellular recognition pathway. In addition, signaling
perturbation experiments implicated an integrated cross-
talk among the members of PI3K, ERK1/2, p38 MAPK, and
NF-B pathways during Rv1917c-induced DC maturation.
These Rv1917c-triggered cellular events resulted in a switch
FIGURE 6. Involvement of PI3K, ERK1/2, p38 MAPK, and NF-B pathways in Rv1917c-induced maturation of DCs. A, DCs were treated with pharmaco-
logical inhibitors of ERK1/2 (U0126, 10 M), p38 MAPK (SB203580, 20 M), PI3K (LY294002, 50 M), NF-B (Bay 11-7082, 20 M; L-1-tosylamido-2-phenylethyl
chloromethyl ketone, 20 M), or DMSO (vehicle control) for 1 h prior to treatment with Rv1917c for 48 h, and the expression of CD80, CD86, and CD40 was
analyzed by flow cytometry. B,DCs were treated as in A, and the level of secreted IL-6, IL-10, and TNF-was analyzed. Data are presented asmean S.E. from
three independent donors. *, p 0.05 versus Rv1917c.MFI, mean fluorescence intensities.
Rv1917c-drivenMaturation of HumanDCs and Th2 Responses
NOVEMBER 19, 2010•VOLUME 285•NUMBER 47 JOURNAL OF BIOLOGICAL CHEMISTRY 36519
 by guest on O
ctober 23, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
of Th1/Th2 balance in favor of the Th2 type of cellular
immunity.
PGE2 is one of the important key regulators of Th1/Th2
polarization (59). PGE2, a biosynthetic product of enzymatic
activity of COX-2, binds to EP2 or EP4 receptor on the cell
surface of immune cells such as DCs or T cells and interferes
with awide range of effector functions (60, 61). Furthermore, in
vitro studies suggest that PGE2 paves a way for the develop-
ment of Th2 response by inhibiting the production of the
Th1 cytokines IL-2 and IFN- as well as augmenting IL-4 and
IL-5 production (59–61). A variety of pathogenic microor-
ganisms, including mycobacteria, activate COX-2 expres-
sion that could lead to suppression of Th1 polarization in
favor of Th2 immunity (51, 56). Additionally, COX-2	/	
mice infected with Helicobacter pylori were shown to have
up-regulated IFN- and IL-12 expression compared with
wild-type mice (61). Accordingly, Rv1917c strongly stimu-
lated COX-2 expression and augmented the secretion of
PGE2 from human DCs. Inhibition of COX-2 activity in DCs
prominently suppressed Rv1917c-induced Th2 responses.
These results clearly implicate a crucial role of the COX-2/
PGE2 axis in the development of Th2 immunity in response
to Rv1917c. Overall, this investigation identifies Rv1917c as
a Th2-responsive mycobacterial antigen that can play a deci-
sive role in controlling the clinical course of tuberculosis.
Importantly, we would like to speculate that our analysis
would render the designing and development of peptido-
mimics that specifically inhibit interaction between Rv1917c
and pattern recognition receptors as well as host signaling
proteins of DCs or macrophages. Because expansion of reg-
ulatory T cells and Th2 cells is a hallmark of chronic tuber-
culosis infection, the molecular adjuvants such as CCR4
antagonists that block these two suppressive populations
might benefit tuberculosis vaccination strategies (79, 80).
These insights, in our opinion, will broaden the understand-
ing of the tuberculosis disease pathogenesis andmight pave a
way for their inclusion in drug development efforts against
tuberculosis.
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Supplementary Figure S1. Subcellular localization of M. tuberculosis Rv1917c. Different 
cellular fractions of virulent M. tuberculosis were probed with anti-Rv1917c polyclonal 
antibodies to delineate the localization of Rv1917c. Lane 1, cell membrane of M. tuberculosis; 
lane 2, cytosol of M. tuberculosis; lane 3, cell wall of M. tuberculosis; lane 4, culture filtrate 
proteins (CFP) of M. tuberculosis; lane 5, purified SH3-interacting domain of Rv1917c. The blot 
is representative of two independent experiments.  
 
 
 
Supplementary Figure S2. 55 kDa fragment encompassing the SH3-interacting domain of 
Rv1917c (Rv1917c-SH3 55kDa) induces maturation of human DCs. Immature DCs were treated 
with 5μg/ml of ‘Rv1917c-SH3 55kDa’ for 48h followed by analysis of cell surface maturation 
markers. The data represents mean fluorescence intensities (MFI) ± SEM from two independent 
donors. *p < 0.05 versus Rv1917c-SH3 55kDa 
 
 
Supplementary Figure S3. Maturation of DCs is specific to Rv1917c. DCs were treated 
with Rv1917c or proteinase K-treated Rv1917c for 48h and surface expression of maturation 
markers CD80, CD83, CD86, CD1a, HLA-DR and CD40 was analyzed. PK, Proteinase K. Data 
are presented as mean ± SEM from two independent donors. *p < 0.05 versus Rv1917c.  
 
 
 
Supplementary Figure S4. PI3K, ERK1/2, p38 MAPK and NF-κB pathways play 
decisive role in Rv1917c-induced maturation of DCs. DCs were treated with pharmacological 
inhibitors of ERK1/2 (U0126), p38 MAPK (SB203580), PI3K (LY294002), NF-κB (Bay11-7082 
and TPCK) or DMSO (vehicle control) for 1h prior to treatment with Rv1917c for 48h followed 
by expression analysis of CD1a, CD83 and HLA-DR by flow cytometry. Data are presented as 
mean ± SEM from three independent donors. *p < 0.05 versus Rv1917c. 
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